In addition, the tumor suppressor gene BAP1 is another biomarker for aggressive meningioma and may also represent a potential therapeutic target because BAP1 inactivation may increase tumor sensitivity to PARP inhibition. This evidence concerns the gene BAP1 and meningioma.